RBC Capital lowered the firm’s price target on Pharming (PHAR) to EUR 2 from EUR 2.15 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group Files 2024 Annual Report and Form 20-F
- Pharming price target raised to $39 from $30 at Oppenheimer
- Pharming Group’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Pharming Group Reports Strong 2024 Revenue Growth
- Pharming Group Expands Stake in Abliva to 92.70%